GEMM tumors are generally poorly immunogenic; however, they can be engineered to express neoAgs to study tumor-immune system interactions.23,53–56 We engineered YUMM1.7 to express known tumor neoAgs via introduction of minigenes encoding the G1254V mutation in Lama4 (mLama4MHC-I), the A506T mutation in Alg8 (mAlg8MHC-I), and the N710Y mutation in Itgb1 (mItgb1MHC-II) neoAgs16,23 in various combinations: mLama4MHC-I + mItgb1MHC-II (Y1.7LI line) or mAlg8MHC-I + mItgb1MHC-II (Y1.7AI line) (Figure S1A). Here, ITGB1 is linked to neoplasm.